In this report we show that induction of YAP is a possible mechanism of drug resistance to EGFR tyrosine kinase inhibitors in NSCLC adenocarcinomas, and that inhibiting this co-transcription factor can re-sensitize the cells to EGFR inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.